Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives $110.43 Average Target Price from Brokerages

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have been given an average recommendation of “Moderate Buy” by the eleven analysts that are presently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $110.4286.

A number of brokerages recently commented on LNTH. Citizens Jmp restated a “market outperform” rating and set a $115.00 target price on shares of Lantheus in a report on Monday, June 29th. Wall Street Zen cut shares of Lantheus from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Weiss Ratings reissued a “hold (c)” rating on shares of Lantheus in a research report on Tuesday, May 26th. Truist Financial upped their price objective on shares of Lantheus from $115.00 to $125.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $94.00 target price on shares of Lantheus in a research report on Thursday, May 7th.

Lantheus Stock Down 3.0%

NASDAQ LNTH opened at $104.40 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.83 and a quick ratio of 2.64. The stock has a market capitalization of $6.80 billion, a PE ratio of 25.16 and a beta of -0.06. Lantheus has a 1 year low of $47.25 and a 1 year high of $111.86. The business’s 50-day moving average is $102.60 and its 200 day moving average is $84.61.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The company had revenue of $377.33 million for the quarter, compared to the consensus estimate of $354.48 million. During the same quarter in the previous year, the business earned $1.53 EPS. Lantheus’s revenue was up 1.2% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Sell-side analysts forecast that Lantheus will post 4.5 earnings per share for the current year.

Institutional Trading of Lantheus

Institutional investors and hedge funds have recently bought and sold shares of the stock. Focus Financial Network Inc. bought a new stake in Lantheus during the 2nd quarter valued at approximately $249,000. Reinhart Partners LLC. grew its holdings in shares of Lantheus by 2.2% during the 2nd quarter. Reinhart Partners LLC. now owns 1,599,379 shares of the medical equipment provider’s stock worth $177,437,000 after acquiring an additional 34,501 shares during the period. Assenagon Asset Management S.A. grew its holdings in shares of Lantheus by 440.3% during the 2nd quarter. Assenagon Asset Management S.A. now owns 714,980 shares of the medical equipment provider’s stock worth $79,320,000 after acquiring an additional 582,661 shares during the period. GAMMA Investing LLC raised its position in shares of Lantheus by 6.4% in the 2nd quarter. GAMMA Investing LLC now owns 3,348 shares of the medical equipment provider’s stock worth $371,000 after acquiring an additional 202 shares in the last quarter. Finally, Versant Capital Management Inc raised its position in shares of Lantheus by 33.0% in the 2nd quarter. Versant Capital Management Inc now owns 588 shares of the medical equipment provider’s stock worth $65,000 after acquiring an additional 146 shares in the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.